Miguel Regueiro, MD

Articles by Miguel Regueiro, MD

Take-Home Messages for the Management of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

January 11th 2023

Experts in gastroenterology share advice for the treatment of patients of Crohn’s disease.

Emerging Therapies and Challenges for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

January 4th 2023

Dr Anita Afzali and Miguel Regueiro discuss emerging therapies and combinations in the pipeline for Crohn’s disease as well as unmet needs in the field for disease management.

Role of Biosimilars for the Management of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

January 4th 2023

Bincy P. Abraham, MD, MS, AGAF, FACG, and Jennifer Seminerio, MD, comment on emerging data for interchangeability of biosimilars and biologics when treating Crohn’s disease.

Using Selective IL-23 Inhibitors for the Treatment of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 28th 2022

Experts in gastroenterology review the use of IL-23 inhibitors such as guselkumab and risankizumab-rzaa for the management of Crohn’s disease.

Selecting Treatment Options for Elderly Patients in Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 28th 2022

Dr Bincy P. Abraham examines age considerations and comorbidities when choosing a therapy for elderly patients with Crohn’s disease.

Real-World Implications of Novel Crohn’s Disease Therapies

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 21st 2022

Anita Afzali, MD, MPH, MHCM, FACG, AGAF, explores clinical implications of newer therapies for Crohn’s disease in the real-world setting.

Durability of IL-12/23 Inhibitors in Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 21st 2022

Jennifer Seminerio, MD, discusses long-term outcomes and clinical remission rates for patients on an IL/23 inhibitor for Crohn’s disease.

IL-23 Inhibitors and IL-12/23 Inhibitors for Crohn’s Disease Management

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 14th 2022

Dr Miguel Regueiro comments on the safety and efficacy of approved IL-23 inhibitors and IL-12/23 inhibitors for the treatment of Crohn’s disease.

Role of IL 12/23 Inhibitors for the Management of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 14th 2022

Jennifer Seminerio, MD, and Bincy P. Abraham, MD, MS, AGAF, FACG, share their perspective on the use of IL-12/23 inhibitors in clinical practice for the management of Crohn’s disease.

Treatment Selection for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 7th 2022

Drs Bincy P. Abraham, Miguel Regueiro, David P. Hudesman, Anita Afzali, and Jennifer Seminerio provide insight on approaching the optimal therapy for patients with Crohn’s disease in the frontline and second-line settings.

Using Biologics in Crohn’s Disease Treatment

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

December 7th 2022

Drs Miguel Regueiro, Jennifer Seminerio, Anita Afzali, and David Hudesman review currently available biologic therapies for moderate-to-severe Crohn’s disease and the evolution of the disease treatment landscape.

Approaching Treatment for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 30th 2022

Dr Bincy P. Abraham leads a discussion on factors to consider when selecting a therapy for the management of Crohn’s disease.

Goals of Therapy for Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 30th 2022

Experts in gastroenterology review goals of therapy for the management of Crohn’s disease, utilizing a treat-to-target approach for treatment, and the importance of shared decision-making.

Diagnosis of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 23rd 2022

Dr Anita Afzali and Dr Bincy P. Abraham review the diagnostic workup for Crohn’s disease and challenges in diagnosing the disease.

Overview of Crohn’s Disease

ByDavid P. Hudesman, MD,Bincy Abraham, MD, MS,Anita Afzali, MD,Miguel Regueiro, MD,Jennifer Seminerio, MD

November 23rd 2022

Bincy P. Abraham, MD, MS, AGAF, FACG, and Jennifer Seminerio, MD, provide insight on the pathophysiology of Crohn’s Disease (CD), associated risk factors, and diagnosis of disease.

Key Takeaways for Ulcerative Colitis Management

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

July 12th 2022

Experts in gastroenterology share take-home messages for the management of ulcerative colitis.

Clinical Pearls for the Treatment of Ulcerative Colitis

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

July 12th 2022

David P. Hudesman, MD; Marla Dubinsky, MD; Ellen J. Scherl, MD; and Miguel Regueiro, MD, provide advice for physicians treating patients with ulcerative colitis.

Future Treatment Paradigms in Ulcerative Colitis

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

July 6th 2022

Drs David P. Hudesman, Ellen J. Scherl, Marla Dubinsky, and Miguel Regueiro, explore novel therapies in the pipeline and discuss approaches to optimizing sequencing and treatment selection for ulcerative colitis.

Sequencing Therapies in Ulcerative Colitis

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

July 6th 2022

Experts in gastroenterology discuss their approach to sequencing therapies in ulcerative colitis, considering safety, efficacy, and access to various treatment regimens and comment on challenges physicians may face when incorporating new therapies into clinical practice.

Ozanimod in Ulcerative Colitis

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 28th 2022

Ellen J. Scherl, MD, reviews data from the phase 3 True North study evaluating the use of ozanimod as induction and maintenance therapy for moderate to severe ulcerative colitis, and the panel shares their experience with ozanimod in clinical practice.

Challenges in UC Treatment

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 28th 2022

Ellen J. Scherl, MD, leads a discussion on challenges faced with traditional ulcerative colitis treatments.

Switching Therapies in Ulcerative Colitis

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 21st 2022

David P. Hudesman, MD, and expert panelists provide insight on optimizing the sequencing of therapies in ulcerative colitis and determining when a change in treatment is needed.

Role of JAK Inhibitors and S1P Receptor Modulators for UC Treatment

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 21st 2022

Marla Dubinsky, MD, discusses the role of S1P receptor modulators and JAK inhibitors for the treatment of ulcerative colitis.

UC Treatment: Anti-integrin Antibodies and Anti-interleukins

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 14th 2022

David P. Hudesman, MD, reviews the use of anti-integrin and anti-interleukin therapies for the management of ulcerative colitis.

Using 5-ASAs and Steroids for UC Treatment

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 14th 2022

Ellen J. Scherl, MD, comments on the limited role of mesalamine and steroids for moderate-to-severe ulcerative colitis treatment.

Approaching Ulcerative Colitis Treatment Selection

ByMiguel Regueiro, MD,David P. Hudesman, MD,Ellen J. Scherl, MD,Marla Dubinsky, MD

June 7th 2022

Marla Dubinsky, MD, emphasizes the role of shared decision-making and patient goals of therapy when approaching treatment selection for ulcerative colitis.